Atara CFO Utpal Koppikar resigns effective March 31; enters six-month consulting agreement

Atara Biotherapeutics, Inc.

Utpal Koppikar resigned as CFO effective March 31, 2023, and entered a six-month consulting agreement.
Consulting fee: $2,800/month for up to a specified number of hours, plus $175/hour for excess hours.
Outstanding equity awards will continue to vest during the consulting term.
No successor named in the filing; search for new CFO is presumably ongoing.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Utpal Koppikar

Executive Vice President, Chief Financial Officer

ATRA · Atara Biotherapeutics, Inc.

Effective: 2023-03-31
Filed: March 31, 2023, 7:59 PM ET

On February 3, 2023, Atara Biotherapeutics, Inc., a Delaware corporation (the “Company”), announced that Utpal Koppikar, the Company’s Executive Vice President, Chief Financial Officer, notified the Company of his intention to resign from the Company effective as of March 31, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Utpal Koppikar resigned as Executive Vice President, Chief Financial Officer at Atara Biotherapeutics, Inc..

Action: resigned
Role: Executive Vice President, Chief Financial Officer

Exact text from the filing

On February 3, 2023, Atara Biotherapeutics, Inc., a Delaware corporation (the “Company”), announced that Utpal Koppikar, the Company’s Executive Vice President, Chief Financial Officer, notified the Company of his intention to resign from the Company effective as of March 31, 2023.

View on SEC.gov

Atara Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-011416

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.